U.S. Inflation Surges in March as Iran War and Tariffs Drive Prices Higher 
Federal Reserve Probes Big Banks Over Private Credit Exposure Amid Growing Systemic Risk Concerns 
U.S. Futures Plunge as Iran Ceasefire Talks Collapse and Hormuz Blockade Looms 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
BCA Research Warns U.S.-Iran Ceasefire Could Collapse, Maintains Cautious Equity Outlook 
Bank of Japan Governor Signals Accommodative Stance Amid Negative Real Rates 
Bank of Korea Governor Nominee Warns of Action if Korean Won Weakens Further 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
China's Inflation Data Misses Forecasts as Consumer Prices Slow in March 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Trump Slams Iran Over Strait of Hormuz Oil Restrictions Amid Fragile Ceasefire 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
U.S. Markets Post Strong Weekly Gains Despite Middle East Tensions and Rising Energy Prices 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
White House Warns Staff Over Insider Trading Amid Suspicious Oil Market Bets 
Pfizer inc., an American pharmaceutical and biotechnology firm headquartered in Manhattan, New York City, has agreed to buy Global Blood Therapeutics biotech company for $5.4 billion. The drugmaker will be paying $68.50 a share for the acquisition.
According to Reuters, Pfizer will purchase the blood disorder medicine producer as it would like to bolster its drug lineup to counter or fight a possible slowdown in the demand for COVID medicines and other products since the cases are starting to fall.
Pfizer was one of the drugmakers that earned the most at the height of the COVID-19 pandemic since it supplied the vaccines around the world. With most people worldwide now fully vaccinated, the company is now looking for acquisitions that will bring in profits annually
Pfizer confirmed on Monday, Aug. 8, that it will be paying $68.50 per share to buy Global Blood Therapeutics. This amount is equivalent to a premium of around 7.3% to the stock's closing price last Friday.
Following the announcement of the deal with Pfizer, the shares of Global Blood reportedly soared by 4.5%. The company is known for its blood disorder drug called Oxbryta, which was first approved in 2019.
It is used for the treatment of sickle cell disease in patients who are 12 years old or older. In December 2021, it was also approved for the treatment of younger patients who are suffering from the said disease.
“Sickle cell disease is the most common inherited blood disorder, and it disproportionately affects people of African descent. We are excited to welcome GBT colleagues into Pfizer and to work together to transform the lives of patients, as we have long sought to address the needs of this underserved community,” Pfizer’s chairman and chief executive officer, Albert Bourla, said in a press release.
He added, “The deep market knowledge and scientific and clinical capabilities we have built over three decades in rare hematology will enable us to accelerate innovation for the sickle cell disease community and bring these treatments to patients as quickly as possible.”
